Under the agreement, Gilead will acquire global rights to develop and commercialize novel small molecules against two undisclosed targets in all countries, with the exception of the Republic of Korea where Yuhan will retain certain commercialisation rights.
Yuhan and Gilead will jointly conduct preclinical research, and Gilead will be responsible for global clinical development.
Gilead will also be responsible for commercialisation worldwide, outside of Yuhan's rights in the Republic of Korea.
In connection with this agreement, Yuhan will receive an upfront payment of USD 15m and is eligible to receive up to an additional USD 770m in potential milestone payments upon achievement of certain development and commercial milestones, as well as royalties on future net sales.
This agreement builds on the companies' existing commercial collaboration to support the promotion of Gilead's medicines in the Republic of Korea.
NASH is a chronic and progressive liver disease characterized by fat accumulation and inflammation in the liver, which can lead to scarring, or fibrosis, that impairs liver function.
Individuals with advanced fibrosis due to NASH, defined as bridging fibrosis or cirrhosis, may face serious consequences, including end-stage liver disease, liver cancer and the need for liver transplantation, and are at a significantly higher risk of liver-related mortality.
Currently, patients living with NASH have limited treatment options.
Yuhan is a South Korea-based healthcare company founded in 1926.
Its core business consists of primary and specialty care, dietary supplements, household and animal care, and contract manufacturing of active pharmaceutical ingredients.
It has a number of subsidiaries and a global presence in the form of joint ventures with the Clorox company and Kimberly-Clark Corp. Yuhan (000100: KS) is a publicly-listed company traded on the Korea Stock Exchange.
Gilead Sciences is a research-based biopharmaceutical company that discovers, develops and commercialises innovative medicines in areas of unmet medical need.
The company strives to transform and simplify care for people with life-threatening illnesses around the world. Gilead has operations in more than 35 countries worldwide, with headquarters in Foster City, California.
Chemomab secures new patents for CM-101 monoclonal antibody
argenx receives FDA priority review for VYVGART Hytrulo in CIDP
AffaMed Therapeutics' DEXTENZA NDA accepted by Singapore regulator
AbbVie showcases gastroenterology portfolio at ECCO Congress
Japan approves Sanofi's Dupixent for chronic spontaneous urticaria
Ono partners with Shattuck Labs for bifunctional fusion proteins
Zymedi commences first in human dosage of ZMA001
Bio-Thera Solutions commences dosing in BAT6026 Phase IA/IIB clinical trial
EicOsis Human Health commences EC5026 Phase 1b multiple-ascending dose clinical trial
Takeda's HyQvia approved for maintenance therapy in CIDP patients
Celltrion USA submits CT-P47 Biologics License Application to FDA
Formosa Pharmaceuticals agrees licensing deal in Brazil for APP13007